- Home
- TCRT vs NXTS Comparison
TCRT vs NXTS Comparison
Compare TCRT & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRT | NXTS |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.1M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TCRT | NXTS |
|---|---|---|
| Price | $0.92 | $1.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 382.8K | 27.5K |
| Earning Date | 11-13-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.66 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,900,000.00 | $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.55 |
| 52 Week High | $4.57 | $23.80 |
Technical Indicators
Market Signals| Indicator | TCRT | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 31.10 | 38.43 |
| Support Level | N/A | $1.21 |
| Resistance Level | $2.09 | $2.08 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 8.18 | 51.91 |
Price Performance
Historical ComparisonAbout TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.